A diagnosis of uveal melanoma marks the beginning of a long-term relationship with your medical team. While the focus starts ...
Sarepta Therapeutics saw its stock skid 11% after the company announced preliminary unaudited 2025 sales results that missed analyst forecasts for its marketed Elevidys® (delandistrogene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback